<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02743156</url>
  </required_header>
  <id_info>
    <org_study_id>Mozart II</org_study_id>
    <nct_id>NCT02743156</nct_id>
  </id_info>
  <brief_title>Minimizing Contrast Utilization With IVUS Guidance in Coronary Angioplasty to Avoid Acute Nephropathy</brief_title>
  <acronym>Mozart-II</acronym>
  <official_title>Minimizing Contrast Utilization With IVUS Guidance in Coronary Angioplasty to Avoid Acute Nephropathy: The MOZART-II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InCor Heart Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InCor Heart Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Contrast-induced acute kidney injury (CI-AKI) is an important adverse effect of percutaneous&#xD;
      coronary interventions. Despite various efforts, very few preventive measures have been shown&#xD;
      effective in reducing its incidence.&#xD;
&#xD;
      The final volume of contrast media utilized during the procedure is a well- known independent&#xD;
      factor affecting the occurrence of CI-AKI.&#xD;
&#xD;
      Intravascular ultrasound (IVUS) has been largely used as an adjunctive diagnostic tool during&#xD;
      percutaneous coronary intervention (PCI). When fully explored, IVUS provides precise&#xD;
      information for guiding PCI, thereby reducing the usage of contrast media. Accordingly, the&#xD;
      recent MOZART study demonstrated that IVUS may lead to a 2-3-fold decrease in the volume of&#xD;
      contrast media during PCI.&#xD;
&#xD;
      In the present study, the hypothesize that IVUS guidance, and its consequent reduction in the&#xD;
      volume of contrast media, will in decrease the risk of CI-AKI after PCI, in comparison to&#xD;
      standard angiography-guided intervention.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Prospective, unblinded, randomized (1:1), multi-center trial of 300 patients allocated&#xD;
           to one of the treatment arms (IVUS-guided PCI or angiography-guided PCI). Aggressive&#xD;
           (non-IVUS) strategies to reduce contrast will be used in both study arms&#xD;
&#xD;
        -  The study population will be composed of patients with renal dysfunction referred for&#xD;
           PCI of one or more coronary vessels, all of them amenable to IVUS imaging&#xD;
&#xD;
        -  After discharge, all subjects will be clinically followed-up for 1 year after the index&#xD;
           procedure, at the following time-points: 30 and 180 days and 1 year.&#xD;
&#xD;
        -  Unless contra-indicated, all patients elective will receive intravenous hydration during&#xD;
           12 hours pre- and 12 hours post-PCI. For patients with acute coronary syndrome,&#xD;
           intensive intravenous hydration should be initiated as early as possible. Saline (NaCl&#xD;
           0.9%) infusion is recommended at a dose of 1 ml / kg body weight per hour, 25 and&#xD;
           reduced to 0.5 ml/kg/h for those at high risk of volume overload (e.g. reduced left&#xD;
           ventricular function or overt heart failure).The use of N-acetylcysteine or sodium&#xD;
           bicarbonate will be left to operator discretion.&#xD;
&#xD;
        -  Operators will be strongly recommended to follow strict strategies to reduce the total&#xD;
           volume of contrast for all patients&#xD;
&#xD;
        -  All percutaneous procedures will be performed using non-ionic, low-osmolar or&#xD;
           iso-osmolar, iodine-based contrast media&#xD;
&#xD;
        -  The study groups will be compared according to the intention-to-treat principle.&#xD;
           Categorical variables will be compared by Fisher's exact testing and continuous&#xD;
           variables by Student's T testing. Time-dependent events will be estimated by the&#xD;
           Kaplan-Meier method and compared by Hazards Cox modeling or log-rank test&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Contrast-induced acute kidney injury</measure>
    <time_frame>72 hours</time_frame>
    <description>Evaluate whether IVUS-guided PCI reduces CI-AKI in&#xD;
comparison to stand-alone angiography-guided PCI. CI-AKI will be defined as&#xD;
an increase in serum creatinine ≥ 0.5 mg/dl from the baseline value, within&#xD;
72 hours after the index procedure (or at discharge).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac events and components</measure>
    <time_frame>one year</time_frame>
    <description>cardiovascular death, myocardial infarction and target vessel revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>one year</time_frame>
    <description>stent thrombosis will be defined as the occurrence of definite or probable stent thrombosis according to the Academic Research Consortium (ARC) criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious acute kidney dysfunction</measure>
    <time_frame>one year</time_frame>
    <description>increase in serum creatinine ≥ 2 mg/dl or need for dialysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure Time</measure>
    <time_frame>procedure time</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiation exposure</measure>
    <time_frame>procedure time</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Acute Kidney Injury</condition>
  <condition>Acute Renal Failure</condition>
  <condition>Acute Renal Injury</condition>
  <arm_group>
    <arm_group_label>angiography-guided PCI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>angiography-guided percutaneous coronary intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IVUS-guided PCI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intravascular ultrasound guided percutaneous coronary intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>IVUS-guided PCI</intervention_name>
    <description>intravascular ultrasound-guided percutaneous coronary intervention</description>
    <arm_group_label>IVUS-guided PCI</arm_group_label>
    <other_name>intravascular ultrasound</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Angiography-guided PCI</intervention_name>
    <description>Angiography-guided percutaneous coronary intervention. This is the conventional treatment.</description>
    <arm_group_label>angiography-guided PCI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age over 18 years&#xD;
&#xD;
          -  Coronary artery disease referred for percutaneous intervention, with stent&#xD;
             implantation, of one or more epicardial vessel.&#xD;
&#xD;
             ----&gt;All target lesions must be amenable to IVUS imaging, as judged by an experienced&#xD;
             interventionalist (lesions not assessable by IVUS at baseline but which are judged to&#xD;
             the assessable at any time during the procedure are eligible).&#xD;
&#xD;
          -  Baseline calculated creatinine clearance &lt; 60 ml/min/1.73 m2 or baseline creatinine &gt;&#xD;
             1.5 mg/dl&#xD;
&#xD;
          -  Ability to sign informed consent and comply with all study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of &gt; 50 ml (single-lesion PCI) or &gt; 70 ml (multi-lesion PCI) of iodinated agents &lt;&#xD;
             72 hours (this restriction includes the contrast used during the diagnostic phase of&#xD;
             ad hoc PCI).&#xD;
&#xD;
          -  Planned use of iodinated contrast within the next 72 hours after the index procedure&#xD;
&#xD;
          -  Use of other nephrotoxic agents &lt; 7 days&#xD;
&#xD;
          -  Known allergy to contrast agents&#xD;
&#xD;
          -  Unstable or unknown renal function prior to PCI.&#xD;
&#xD;
          -  Prior PCI of the target lesions&#xD;
&#xD;
          -  Patients requiring additional surgery (cardiac or non cardiac) within 72 hours after&#xD;
             the index procedure&#xD;
&#xD;
          -  Non cardiac co-morbidities with life expectancy less than 1 year&#xD;
&#xD;
          -  Other investigational drug or device studies that have not reached their primary&#xD;
             endpoint&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedro A. Lemos, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heart Institute - InCor. University of Sao Paulo Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patricia Pereira</last_name>
    <phone>+551126615368</phone>
    <email>patricia@incor.usp.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Heart Institute - InCor. University of Sao Paulo Medical School</name>
      <address>
        <city>São Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pedro A Lemos, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>José Mariani Jr, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunha</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salvatore Brugaletta</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>April 10, 2016</study_first_submitted>
  <study_first_submitted_qc>April 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2016</study_first_posted>
  <last_update_submitted>April 24, 2016</last_update_submitted>
  <last_update_submitted_qc>April 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>InCor Heart Institute</investigator_affiliation>
    <investigator_full_name>Pedro A. Lemos</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>IVUS</keyword>
  <keyword>Acute Renal Failure</keyword>
  <keyword>Angioplasty</keyword>
  <keyword>stent</keyword>
  <keyword>contrast</keyword>
  <keyword>percutaneous coronary intervention</keyword>
  <keyword>intravascular ultrasound</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

